MARKET

INAB

INAB

In8Bio, Inc.
NASDAQ
0.1720
-0.0060
-3.37%
Closed 19:54 04/29 EDT
OPEN
0.1856
PREV CLOSE
0.1780
HIGH
0.1900
LOW
0.1704
VOLUME
796.90K
TURNOVER
--
52 WEEK HIGH
1.740
52 WEEK LOW
0.1330
MARKET CAP
13.98M
P/E (TTM)
-0.3026
1D
5D
1M
3M
1Y
5Y
1D
IN8bio’s Promising T Cell Engager Program and Strategic Developments Earns Buy Rating
TipRanks · 1d ago
IN8bio announces new preclinical data from gamma-delta T cell engager platform
TipRanks · 1d ago
IN8bio Unveils New Data from Next Generation Gamma-Delta T Cell Engager Platform At AACR 2025
Benzinga · 1d ago
Weekly Report: what happened at INAB last week (0421-0425)?
Weekly Report · 2d ago
Weekly Report: what happened at INAB last week (0414-0418)?
Weekly Report · 04/21 09:38
Weekly Report: what happened at INAB last week (0407-0411)?
Weekly Report · 04/14 09:35
Weekly Report: what happened at INAB last week (0331-0404)?
Weekly Report · 04/07 09:35
Weekly Report: what happened at INAB last week (0324-0328)?
Weekly Report · 03/31 09:38
More
About INAB
More
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Recently
Symbol
Price
%Change

Webull offers IN8bio Inc stock information, including NASDAQ: INAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INAB stock methods without spending real money on the virtual paper trading platform.